Health Care Distributors

CQP released FY2025 Annual Earnings on April 23 After-Market (BJT), Actual Revenue CNY 82.45B (Forecast CNY 90.19B), Actual EPS CNY 0.22 (Forecast CNY 0.51)

CQP released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 20.24 B, actual EPS CNY 0.0015

CQP released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 20.43 B, actual EPS CNY 0.1

CQP FY2026 Q1 Earnings Release Scheduled for April 24 After-Market BJT

CQP to Release FY2025 Annual Earnings on April 24, After-Market (BJT), Forecast Revenue CNY 90.19 B, EPS CNY 0.51

CQP released FY2025 Q3 earnings on October 27 Pre-Market (BJT), actual revenue CNY 21.02 B, actual EPS CNY 0.0595

CQP released FY2025 9 Months Earnings on October 27 Pre-Market (BJT), actual revenue CNY 62.21 B, actual EPS CNY 0.2198

CQP to Release FY2025 Q3 Earnings on October 28 Pre-Market BJT

CQP released FY2025 Semi-Annual earnings on August 20 After-Market (BJT), actual revenue CNY 41.19 B, actual EPS CNY 0.16

CQP released FY2025 Q2 earnings on August 20 After-Market (BJT), actual revenue CNY 20.58 B, actual EPS CNY 0.0902

CQP FY2025 Semi-Annual Earnings Release on August 21, 2025 (BJT)

Investor Suggests Chongqing Pharmaceutical Group to Transform into Veterinary Medicine Industry

Chongqing Holdings Plans to Repurchase Shares

Chongyao Holding Expected Net Profit Growth in First Half of 2025

Four Products of Chongqing Medicine Passed Consistency Evaluation

Chongyu Holding Constructs Intelligent Logistics System

Chongqing Pharmaceutical Group's Prasugrel Hydrochloride Clinical Trial Application Accepted

Chongqing Pharmaceutical Holdings Operating Innovative Drug Sales and Enriching Product Line

Chongqing Pharmaceutical Holdings Obtains National Distribution Rights for Hawk Tea Craft Beer

Chongqing Pharmaceutical Holdings Announces 2024 Annual Report: Revenue of 80.562 Billion, Dividend Plans

000950

301126

600829

300937

000411

A-share pharmaceutical commercial stocks continue to decline, with Shuyu Pingmin dropping over 18%. HRPC, DAJIAWEIKANG, INT'L GROUP, and Hezong Medicine Easy-To-Buy Pharmaceutical all fell more than 5%, while Huaren Health, CQP, and Kaikai Industry also followed suit

Wallstreetcn

DAJIAWEIKANG

HRPC

Hezong Medicine Easy-To-Buy Pharmaceutical

INT'L GROUP

CQP announced that the company plans to repurchase shares in July 2025, with a total funding amount of 80 million to 100 million yuan, and the repurchase price not exceeding 6.6 yuan per share, with a duration of 12 months. As of October 31, the company has cumulatively repurchased 15.4066 million shares, accounting for 0.8915% of the total share capital, with a highest transaction price of 5.48 yuan per share and a lowest of 5.01 yuan per share, totaling a payment amount of 80.9988 million yuan. The company will continue to implement the repurchase according to the plan and disclose information in a timely manner

Zhitong

CQP: As of the end of October, a total of RMB 80.9988 million has been spent to repurchase shares

On October 31, General Technology CQP signed a strategic cooperation agreement with Johnson & Johnson Innovation Pharmaceuticals. According to the agreement, both parties will fully leverage their platform resources and professional technical advantages, focusing on key aspects of controlled substances channel management, and collaboratively promote the channel management of controlled substances towards higher standards, stricter regulations, and better efficiency, jointly creating a controlled substances supply chain system that is patient-centered while ensuring drug accessibility and safety

General Technology CQP signs strategic cooperation agreement with Johnson & Johnson Innovation Pharmaceuticals

On October 27th, CQP announced that in the third quarter of 2025, it achieved operating revenue of 21.023 billion yuan, a year-on-year increase of 5.57%; the net profit attributable to shareholders of the listed company was 102 million yuan, a year-on-year increase of 87.94%; basic earnings per share were 0.06 yuan. In the first three quarters, it achieved operating revenue of 62.211 billion yuan, a year-on-year increase of 4.22%; the net profit attributable to shareholders of the listed company was 384 million yuan, a year-on-year increase of 31.41%

CQP: In the third quarter, the net profit attributable to the parent company was 102 million yuan, an increase of 87.94% year-on-year

CQP expects its net profit for the first three quarters of 2025 to be 358 million yuan, a year-on-year increase of 22.51%-36.88%. The net profit after deducting non-recurring gains and losses is expected to be 348 million yuan, a year-on-year increase of 25.48%-40.62%. The basic earnings per share are expected to be 0.2 yuan/share. The company's various businesses continue to develop, with steady growth in operating revenue

CQP: It is expected that the net profit for the first three quarters will increase by 22.51%-36.88% year-on-year

CQP announced that its holding subsidiary Chongqing Pharmaceutical has received approval from the National Medical Products Administration to conduct clinical trials for Prasugrel Hydrochloride Tablets. This medication is used to prevent cardiovascular diseases such as acute coronary syndrome and is currently marketed in over 70 countries worldwide, but has not yet been launched in China

CQP: The clinical trial for hydrochloride prasugrel tablets has been approved

On August 29th, China General Technology, CQP, and General Health officially signed a strategic cooperation agreement. This signing is not only a positive response and implementation of China General Technology Group's strategic deployment to accelerate the coordinated development of the pharmaceutical and healthcare sectors but also an important practice for the three parties to build a long-term and stable cooperative relationship and jointly promote the high-quality development of the pharmaceutical and healthcare industry through "strong alliances and complementary advantages."

General Technology China Pharmaceutical, together with General Technology CQP and General Health, officially launches strategic cooperation

CQP released its semi-annual report for 2025, reporting operating revenue of 41.188 billion yuan, a year-on-year increase of 3.54%; net profit attributable to shareholders of the parent company was 282 million yuan, a year-on-year increase of 18.56%; net profit excluding non-recurring gains and losses was 277 million yuan, a year-on-year increase of 26.68%; basic earnings per share were 0.16 yuan

CQP released its performance for the first half of the year, with a net profit attributable to the parent company of 282 million yuan, a year-on-year increase of 18.56%

CQP announced that on August 14, 2025, the company will first implement a share repurchase through a dedicated repurchase securities account using a centralized bidding method. The number of shares to be repurchased is 3.7623 million shares, accounting for approximately 0.2177% of the company's current total share capital. The highest transaction price is RMB 5.34 per share, the lowest transaction price is RMB 5.29 per share, and the total payment amount is RMB 19.9993 million. This repurchase complies with the relevant regulations of laws, normative documents, and the requirements of the company's share repurchase plan

CQP: First repurchase of 0.2177% of the company's shares, with a total payment amount of 19.9993 million yuan

CQP announced that as of July 31, 2025, the company has not yet implemented this repurchase. The company plans to use its own funds and a special loan for stock repurchase to repurchase the issued ordinary shares of RMB through the centralized bidding trading method in the Shenzhen Stock Exchange trading system, aimed at reducing the company's registered capital. The total amount of funds used for the repurchase of shares will not be less than RMB 80 million and not exceed RMB 100 million, with a repurchase price not exceeding RMB 6.6 per share, and the repurchase period will be within 12 months from the date of the shareholders' meeting approving the repurchase of shares

CQP: The repurchase has not yet been implemented

CQP(000950.SZ)